European Patent Organisation

Cantargia Reports Filing of Opposition Against Cantargia Patent in Europe

Retrieved on: 
Thursday, October 10, 2019
Intellectual property law, Law by country, Patent law, European Patent Organisation, Opposition proceeding, Patent, Opposition procedure before the European Patent Office, Outline of patents

The current opponent, Mab Discovery GmbH, also filed an opposition against the mother patent in 2016.

Key Points: 
  • The current opponent, Mab Discovery GmbH, also filed an opposition against the mother patent in 2016.
  • That opposition was unsuccessful and the mother patent, valid until 2032, remains in force after the opposition proceedings were concluded in 2018.
  • These patent families concerning IL1RAP comprise more than 80 granted patents and almost 30 additional pending patent applications worldwide.
  • Mab Discovery has now filed an opposition against that patent, and the next step is a formal procedure where Cantargia is invited to comment on the opposition.

Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

Retrieved on: 
Monday, October 7, 2019
Psychiatry, Patent law, European Patent Organisation, Military, Articles, Opposition proceeding, Trademark law, Posttraumatic stress disorder, Tonix Pharmaceuticals

This patent was originally granted by the EPO in September 2017 and an opposition was filed against the patent in June 2018.

Key Points: 
  • This patent was originally granted by the EPO in September 2017 and an opposition was filed against the patent in June 2018.
  • In addition to these patents, Tonix owns patents covering TNX-102 SL and its use to treat PTSD in the U.S., Europe, and other countries.
  • said, We believe that the outcome of the European opposition proceedings adds strength to the overall patent estate for TNX-102 SL.
  • Tonixs lead program is for the development of Tonmya* (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD.

Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease

Retrieved on: 
Wednesday, October 2, 2019
Law by country, Politics by country, Intellectual property law, European Patent Organisation, Patent law, Monopoly, Patent, European Patent Convention, Unitary patent, European Patent Office

Kalytera has exclusive worldwide rights to this patent through an Exclusive License Agreement with MOR Research Applications, Ltd. of Israel.

Key Points: 
  • Kalytera has exclusive worldwide rights to this patent through an Exclusive License Agreement with MOR Research Applications, Ltd. of Israel.
  • Securing a European patent for this proprietary technology represents an important step forward for Kalytera in its program to develop and commercialize CBD for prevention and treatment of this serious and life-threatening disease.
  • We are delighted to receive this Notice of Allowance from the European Patent Office, said Robert Farrell, J.D., Kalyteras President and Chief Executive Officer.
  • To complete the procedures for issuance of this EU patent, Kalytera must prepare and file translations of the patent claims into French and German.

2-Day Interactive Seminar: United States Patent Practice (London, United Kingdom - December 5-6, 2019)

Retrieved on: 
Monday, September 30, 2019
Law by country, Politics by country, Intellectual property law, Patent law, European Patent Organisation, Monopoly, Patent, United States patent law, European Patent Convention, Outline of patents, Patent prosecution

Are you up to date with the latest court decisions and best practice?

Key Points: 
  • Are you up to date with the latest court decisions and best practice?
  • This highly interactive seminar will give you a comprehensive understanding of the US patent system and enable you to work more effectively with your US counterparts.
  • It highlights the important differences between US and European patent practice and gives you the opportunity for in-depth discussions about prosecution practice and procedure throughout the two days.
  • Offering a wide-ranging and detailed understanding, this seminar covers what every European patent practitioner should know about US patent practice.

Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

Retrieved on: 
Wednesday, September 11, 2019
Law by country, Intellectual property law, Politics by country, European Patent Organisation, Patent law, Amines, Betahistine, Vasodilators, Patent claim, European Patent Convention, European Patent Office, Composition of matter

In addition, the Company received an Intention to Grant notice from the European Patent Office (EPO) for its related patent application entitled Intranasal Composition Comprising Betahistine (European Patent Application 18 703 749.4).

Key Points: 
  • In addition, the Company received an Intention to Grant notice from the European Patent Office (EPO) for its related patent application entitled Intranasal Composition Comprising Betahistine (European Patent Application 18 703 749.4).
  • The allowed claims cover composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery.
  • Auris Medical also has filed corresponding patent applications that will allow the Company to seek similar patent protection in other key markets throughout the world.
  • Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.

Immutep Granted European Patent for Eftilagimod Alpha in Cancer

Retrieved on: 
Thursday, August 22, 2019
Law by country, Intellectual property law, Politics by country, European Patent Organisation, Immutep, Eftilagimod alpha, Divisional patent application, Divisional applications under the European Patent Convention, Patent application, Patent family, European Patent Convention, European Patent Office

SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 2601962) entitled LAG-3 dosage regime for use in the treatment of cancer by the European Patent Office.

Key Points: 
  • SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 2601962) entitled LAG-3 dosage regime for use in the treatment of cancer by the European Patent Office.
  • This European patent was filed as a divisional application, and follows the grant of the European parent patent and two other European divisional patents from the same family, as previously announced to the market.
  • A divisional application is a subsequent application filed from either the original (parent) application or an earlier divisional application.
  • Importantly, the granted patent claims support the application of eftilagimod alpha (efti or IMP321), which is a derivative of LAG-3, in Immuteps ongoing clinical trials, including AIPAC, TACTI-mel, TACTI-002 and INSIGHT-004.

Estar Medical: Regenlab is in Breach of UK Court Orders Following Revocation of its PRP Patent

Retrieved on: 
Thursday, August 15, 2019
Law by country, Intellectual property law, Politics by country, European Patent Organisation, Patent law, European patent law, European Patent Office, European Patent Convention, Patent claim, Patent

HOLON, Israel, Aug. 15, 2019 /PRNewswire/ -- Estar Technologies Ltd. (Estar Medical) announced today that Regenlab failed to pay legal costs resulting from two orders made by the UK High Court (Patent Court).

Key Points: 
  • HOLON, Israel, Aug. 15, 2019 /PRNewswire/ -- Estar Technologies Ltd. (Estar Medical) announced today that Regenlab failed to pay legal costs resulting from two orders made by the UK High Court (Patent Court).
  • The Patent Court awarded Estar Medical extensive legal costs after it revoked the Regenlab PRP patent in its entirety.
  • The Patent Court judgment is in line with the decision of theOpposition Division of the European Patent Office(EPO) which also revoked Regenlab PRP patent in its entirety for lack of novelty and added mater.
  • The EPO and UK judgments add to Estar Medical's winning the infringement claim in Germany last year and the venue judgment inFederal Court in New Yorkin whichRegenlab also lost against Estar Medical.

Estar Medical: Regenlab is in Breach of UK Court Orders Following Revocation of its PRP Patent

Retrieved on: 
Thursday, August 15, 2019
Law by country, Politics by country, Intellectual property law, European Patent Organisation, European Patent Convention, Patent, European Patent Office, Aerotel Ltd v Telco Holdings Ltd, Unitary patent

Regen Lab SA (Regenlab) has failed to pay legal costs ordered by the UK High Court after revocation of its PRP patent for lack of novelty and inventive step.

Key Points: 
  • Regen Lab SA (Regenlab) has failed to pay legal costs ordered by the UK High Court after revocation of its PRP patent for lack of novelty and inventive step.
  • Regenlab is exposed to enforcement procedures which may limit its ability to provide products in the marketplace
    HOLON, Israel, Aug. 15, 2019 /PRNewswire/ -- Estar Technologies Ltd. (Estar Medical) announced today that Regenlab failed to pay legal costs resulting from two orders made by the UK High Court (Patent Court).
  • The Patent Court awarded Estar Medical extensive legal costs after it revoked the Regenlab PRP patent in its entirety.
  • The Patent Court judgment is in line with the decision of theOpposition Division of the European Patent Office(EPO) which also revoked Regenlab PRP patent in its entirety for lack of novelty and added mater.

European Patent Office Opens Up Public Voting for European Inventor Award 2019 Popular Prize

Retrieved on: 
Tuesday, June 4, 2019
Intellectual property law, European Patent Organisation, Law, Countries, European Patent Office, European Inventor Award, EPO, European Patent Convention, Inventor

MUNICH, Germany, June 04, 2019 /PRNewswire-PRWeb/ --The European Patent Office (EPO) invites members of the public to vote for their favorite inventor to receive the European Inventor Award 2019 Popular Prize.

Key Points: 
  • MUNICH, Germany, June 04, 2019 /PRNewswire-PRWeb/ --The European Patent Office (EPO) invites members of the public to vote for their favorite inventor to receive the European Inventor Award 2019 Popular Prize.
  • The winner of the Popular Prize will be announced by the EPO at this year's award ceremony in Vienna on June 20th.
  • In the Industry category, the European Inventor Award 2019 finalists have been nominated in fields as diverse as plastic recycling, breakwater construction and agriculture.
  • With around 7,000 staff, the European Patent Office (EPO) is one of the largest public service institutions in Europe.

US Patent Practice Seminar: Are You up to Date with the Latest Court Decisions and Best Practice - London, United Kingdom - December 5-6, 2019

Retrieved on: 
Thursday, May 30, 2019
Intellectual property law, Law, Countries, Patent law, European Patent Organisation, Law in the United Kingdom, Patent attorney, Patent, United States patent law, European Patent Convention, Outline of patents, Patent prosecution

US Patent Practice, What European patent attorneys need to know.

Key Points: 
  • US Patent Practice, What European patent attorneys need to know.
  • A 2-day highly interactive seminar
    The area of US patent practice can be complex and confusing.
  • Are you up to date with the latest court decisions and best practice?
  • Offering a wide-ranging and detailed understanding, this seminar covers what every European patent practitioner should know about US patent practice.